Antengene Announces its US Partner, Karyopharm Therapeutics Inc., has received FDA Approval …
Antengene Announces its US Partner, Karyopharm Therapeutics Inc., has received FDA Approval … –Oral XPOVIO® Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prior Therapy Significantly Expands the XPOVIO® Addressable Patient Population – — Oral XPOVIO® is Now the Only Approved Multiple Myeloma Drug Indicated as Part of a Once-Weekly […]
Read More